Syngene International profit and loss

Latest FY26

Revenue: ₹3,739cr+2.6% on FY25
EBITDA: ₹919cr−11.8% on FY25
Net profit: ₹317cr−36.2% on FY25
EPS: ₹7.87−36.3% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	3,522	3,739	3,642	3,489	3,193	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	90.9	70.7	71.8	90.6	70.9
	3,613	3,809	3,714	3,579	3,264
	825	911	925	874	902
	9.1	7.4	17.1	56.6	−42.0
	1,100	1,105	984	889	842
	43.6	48.8	53.1	47.2	45.2
	449	453	433	426	367
	837	797	674	655	557
	3,264	3,322	3,086	2,947	2,670
	751	919	1,042	1,014	934
	302	466	609	589	568
Profit
	349	488	628	632	594
	−96.8	−76.6	32.0	−11.1	0.0
	252	411	660	621	594
	56.0	87.0	138	123	117
	10.1	7.2	25.3	−12.2	12.2
	66.1	94.2	164	111	129
	186	317	496	510	464
	186	317	496	510	464
	−32.6	−196	−14.7	143	−97.2
	154	121	482	653	367
	—	317	496	—	464
Per share
	₹4.63	₹7.87	₹12.35	₹12.71	₹11.59
	₹4.62	₹7.87	₹12.34	₹12.69	₹11.51
Other comprehensive income — detail
	−32.6	−196	−14.7	—	—
	−4.1	−6.3	2.9	−11.9	17.0
	−0.8	−1.6	0.9	—	—
	—	—	—	−3.9	3.7
	−45.6	−268	−21.1	199	−144
	−16.3	−76.6	−4.4	—	—
	—	—	—	48.7	−33.9
Per share — as-filed variants
	₹4.63	₹7.87	₹12.35	₹12.71	₹11.59
	₹4.62	₹7.87	₹12.34	₹12.69	₹11.51
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	2,688	2,820	2,700	2,558	2,333
	76.3%	75.4%	74.1%	73.3%	73.1%
Adjusted (ex-exceptional items) — derived
	349	488	628	632	594
	−96.8	−76.6	32.0	−11.1	0.0
	258	376	472	519	464
	₹6.41	₹9.34	₹11.75	₹12.94	₹11.59

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SYNGENE₹398.60

Syngene International Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersSAILIFE DIVISLAB WOCKPHARMA GLAND ASTERDM PPLPHARMA COHANCE LALPATHLABMcap ₹16,060 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Revenue from Operations	3,192.9	3,488.6	3,642.4	3,738.7	3,522.3
Other Income	70.9	90.6	71.8	70.7	90.9
Total Income	3,263.8	3,579.2	3,714.2	3,809.4	3,613.2
Expenses
+ Cost of Materials Consumed	902.2	873.6	925.4	911.2	825.4
+ Changes in Inventories	-42.0	56.6	17.1	7.4	9.1
+ Employee Benefit Expense	841.7	888.7	983.9	1,104.9	1,100.0
+ Finance Costs	45.2	47.2	53.1	48.8	43.6
+ Depreciation & Amortisation	366.5	425.9	432.6	452.9	449.1
+ Other Expenses	556.6	655.3	674.2	796.7	837.0
Total Expenses	2,670.2	2,947.3	3,086.3	3,321.9	3,264.2
EBITDA	934.4	1,014.4	1,041.8	918.5	750.8
EBIT	567.9	588.5	609.2	465.6	301.7
Profit
PBT before Exceptional Items	593.6	631.9	627.9	487.5	349.0
+ Exceptional Items	0.0	-11.1	32.0	-76.6	-96.8
Pretax Income	593.6	620.8	659.9	410.9	252.2
+ Current Tax	117.0	123.0	138.4	87.0	56.0
+ Deferred Tax	12.2	-12.2	25.3	7.2	10.1
Tax Expense	129.2	110.8	163.7	94.2	66.1
Net Income	464.4	510.0	496.2	316.7	186.1
+ Net Income — Continuing Ops	464.4	510.0	496.2	316.7	186.1
+ Other Comprehensive Income	-97.2	142.6	-14.7	-196.0	-32.6
Total Comprehensive Income	367.2	652.6	481.5	120.7	153.5
Net Income to Common	464.4	—	496.2	316.7	—
Per Share
Basic EPS	11.59	12.71	12.35	7.87	4.63
Diluted EPS	11.51	12.69	12.34	7.87	4.62
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-14.7	-196.0	-32.6
+ Items NOT to be Reclassified to P&L	17.0	-11.9	2.9	-6.3	-4.1
+ Tax on Items NOT to be Reclassified	—	—	0.9	-1.6	-0.8
+ Tax on Items NOT to be Reclassified — alt tag	3.7	-3.9	—	—	—
+ Items to be Reclassified to P&L	-144.4	199.3	-21.1	-267.9	-45.6
+ Tax on Items to be Reclassified	—	—	-4.4	-76.6	-16.3
+ Tax on Items to be Reclassified — alt tag	-33.9	48.7	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	11.59	12.71	12.35	7.87	4.63
Diluted EPS — Continuing Operations	11.51	12.69	12.34	7.87	4.62
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	2,332.7	2,558.4	2,699.9	2,820.1	2,687.8
Gross Margin %	73.06	73.34	74.12	75.43	76.31
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	593.6	631.9	627.9	487.5	349.0
− Exceptional Items (reconciliation)	0.0	-11.1	32.0	-76.6	-96.8
Net Income Adj (tax-effected)	464.4	519.1	472.1	375.7	257.5
EPS Adj	11.59	12.94	11.75	9.34	6.41
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	401.4	402.0	402.5	402.9	403.7

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.